MOUNTAIN VIEW, Calif., Feb. 23, 2011 /PRNewswire/ — MAP
Pharmaceuticals, Inc. (Nasdaq:
MAPP) today announced that the Company will participate in the
following investor conferences in March: Citi’s 2011 Global
Healthcare Conference
Wednesday, March 2, at 3:30 p.m. ET in New YorkRBC Capital
Markets’ Healthcare Conference
Thursday, March 3, at 10:00 a.m. ET in New YorkCowen and Company
31st Annual Healthcare Conference
Wednesday, March 9, at 10:15 a.m. ET in BostonBarclays Capital
2011 Global Healthcare Conference
Wednesday, March 16, at 11:15 a.m. ET in MiamiA live webcast of
each event will be available on the Investor Relations section of
MAP Pharmaceuticals’ website at http://www.mappharma.com. A
replay also will be available within 24 hours for seven days
following the presentation.
About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging
biopharmaceutical company focused on developing and commercializing
new therapies to address undermet patient needs in neurology. The
Company is developing LEVADEX orally inhaled therapy for the
potential treatment of migraine and has reported positive results
from the efficacy portion of its Phase 3 trial of LEVADEX. In
addition, MAP Pharmaceuticals generates new pipeline opportunities
by applying its proprietary drug particle and inhalation
technologies to enhance the therapeutic benefits of proven drugs,
while minimizing risk by capitalizing on their known safety,
efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found
at http://www.mappharma.com.
CONTACTS:Lisa BorlandMAP Pharmaceuticals, Inc.(650) 386-3122
lborland@mappharma.com
‘/>”/>
SOURCE
